DBS Sticks to Its Buy Rating for XPeng, Inc. ADR (XPEV)
XPeng, Inc.: Strong Buy Rating Driven by Promising Growth, Technological Advancements, and Increased Sales Projections
XPeng Analyst Ratings
China Renaissance Upgrades XPeng to Buy From Hold, Raises Price Target to $16.70 From $7.70
DBS Maintains XPeng(XPEV.US) With Buy Rating, Raises Target Price to $15
Barclays Maintains XPeng(XPEV.US) With Sell Rating, Cuts Target Price to $7
XPeng, Inc. ADR (XPEV) Receives a Sell From Barclays
XPeng Target Price Raised to $17.80 From $9.10 by CCB International >XPEV
XPeng Is Maintained at Market Perform by Bernstein
XPeng Analyst Ratings
Bernstein Maintains XPeng(XPEV.US) With Hold Rating, Raises Target Price to $14
CMB International Upgrades XPeng to Buy, Price Target Is $16
Citi Maintains XPeng(XPEV.US) With Hold Rating, Cuts Target Price to $13.7
BofA Securities Maintains XPeng(XPEV.US) With Buy Rating, Maintains Target Price $16.2
XPeng Target Price Raised to HK$54.00 From HK$35.00 by Bernstein >XPEV
BofA Securities Maintains XPeng(XPEV.US) With Buy Rating, Raises Target Price to $16.2
J.P. Morgan Maintains XPeng(XPEV.US) With Buy Rating, Raises Target Price to $16
Morgan Stanley Maintains XPeng(XPEV.US) With Buy Rating, Raises Target Price to $17
Citi Maintains XPeng(XPEV.US) With Hold Rating, Maintains Target Price $14.6
J.P. Morgan Maintains XPeng(XPEV.US) With Buy Rating, Maintains Target Price $14